-
Prandoni P, Taher A.
Insights from the dabigatran versus warfarin trial in patients with venous thromboembolism (the RE-COVER trial).
Expert Opin Pharmacother 2010;11(6):1035-7
-
Stangier J, Rathgen K, Stähle H, Mazur D.
Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.
Clin Pharmacokinet 2010;49(4):259-68
-
Audebert HJ, Schenk B, Schenkel J, Heuschmann PU.
Impact of prestroke oral anticoagulation on severity and outcome of ischemic and hemorrhagic stroke in patients with atrial fibrillation.
Cerebrovasc Dis 2010;29(5):476-483
-
Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY.
A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey.
Chest 2010 Mar 18. [Epub ahead of print]
-
Teachey DT.
Dabigatran versus warfarin for venous thromboembolism.
N Engl J Med 2010;362(11):1050